Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Metabolism of [14C]-BI 201335 in Healthy Males
NCT02182349Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2009
- Primary completion
- Jul 2009
- Modality
- Small Molecules, Modified Peptides
01
Overview
Phase 1, open-label, single-arm trial of faldaprevir in hepatitis C (HCV), sponsored by Boehringer Ingelheim. Primary endpoints: Individual concentration-time profiles of [14C]-radioactivity in whole blood, plasma, saliva, urine, and faeces up to 28 days, Individual concentration-time profiles of BI 201335 ZW in plasma and urine up to 28 days and 10 more. Started Jun 2009; status: completed.
02
Drugs
faldaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02182349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182349.